Cantini et al. reported that baseline statin use was significantly related to an improved response rate, PFS, and OS in malignant pleural mesothelioma and NSCLC patients treated with PD-1 inhibitors [18]. Here, PDCD1 is linked to malignant pleural mesothelioma.